NASDAQ:PPBT Purple Biotech (PPBT) Stock Price, News & Analysis $0.40 +0.03 (+8.11%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.36▼$0.4050-Day Range$0.34▼$0.8652-Week Range$0.30▼$1.80Volume104,331 shsAverage Volume212,300 shsMarket Capitalization$10.09 millionP/E RatioN/ADividend YieldN/APrice Target$10.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Purple Biotech alerts: Email Address Purple Biotech MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside2,400.6% Upside$10.00 Price TargetShort InterestHealthy1.60% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.57Based on 5 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.52) to ($0.46) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.80 out of 5 stars 3.5 Analyst's Opinion Consensus RatingPurple Biotech has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePurple Biotech has only been the subject of 1 research reports in the past 90 days.Read more about Purple Biotech's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.60% of the outstanding shares of Purple Biotech have been sold short.Short Interest Ratio / Days to CoverPurple Biotech has a short interest ratio ("days to cover") of 1.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Purple Biotech has recently decreased by 48.86%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldPurple Biotech does not currently pay a dividend.Dividend GrowthPurple Biotech does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PPBT. Previous Next 2.0 News and Social Media Coverage News SentimentPurple Biotech has a news sentiment score of 0.57. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Purple Biotech this week, compared to 0 articles on an average week.Search InterestOnly 2 people have searched for PPBT on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Purple Biotech to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Purple Biotech insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.98% of the stock of Purple Biotech is held by insiders.Percentage Held by InstitutionsOnly 9.64% of the stock of Purple Biotech is held by institutions.Read more about Purple Biotech's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Purple Biotech are expected to grow in the coming year, from ($0.52) to ($0.46) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Purple Biotech is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Purple Biotech is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPurple Biotech has a P/B Ratio of 0.29. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Purple Biotech's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About Purple Biotech Stock (NASDAQ:PPBT)Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 2 clinical trial for the treatment of pancreatic ductal adenocarcinoma; NT219, a small molecule that targets and inhibits insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment recurrent and/or metastatic squamous cell carcinoma of the head and neck cancer or colorectal adenocarcinoma; and IM1240, a multi-valent antibody designed to activate anti-tumoral immune response against 5T4-positive tumors, which is in preclinical stage. The company has collaboration agreement with Bristol Myers Squibb Company to evaluate the combination of CM24 with the PD-1 inhibitor nivolumab in addition to chemotherapy. The company was formerly known as Kitov Pharma Ltd and changed its name to Purple Biotech Ltd. in December 2020. The company is headquartered in Rehovot, Israel.Read More PPBT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PPBT Stock News HeadlinesJuly 25 at 10:42 AM | finanznachrichten.dePurple Biotech Ltd.: Purple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price RuleJuly 25 at 10:42 AM | finance.yahoo.comPurple Biotech Receives Extension to Regain Compliance with the Nasdaq’s Minimum Bid Price RuleJuly 27, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.July 25 at 7:35 AM | globenewswire.comPurple Biotech Receives Extension to Regain Compliance with the Nasdaq's Minimum Bid Price RuleJuly 10, 2024 | globenewswire.comPurple Biotech to Host Virtual KOL Event to Discuss Positive Interim Results from Phase 2 Pancreatic Cancer Study with CM24 on July 11, 2024July 2, 2024 | globenewswire.comPurple Biotech Announces Closing of Exercise of Warrants for $2 Million Gross ProceedsJuly 1, 2024 | globenewswire.comPurple Biotech Announces Exercise of Warrants for $2 Million Gross ProceedsJune 27, 2024 | globenewswire.comPurple Biotech Reports Additional Positive Interim Results from its Randomized Phase 2 Pancreatic Cancer Study with CM24 Regarding a Potential Predictive Biomarker for Overall Survival BenefitJuly 27, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.June 1, 2024 | globenewswire.comPurple Biotech Announces Positive Late-Breaking Interim Randomized Phase 2 Data at ASCO 2024 Demonstrating CM24 Improved Overall Survival and other Efficacy Endpoints in Pancreatic CancerMay 21, 2024 | finanznachrichten.dePurple Biotech Ltd.: Purple Biotech Reports First Quarter 2024 Financial ResultsMay 21, 2024 | msn.comPPBT Stock Earnings: Purple Biotech Beats EPS for Q1 2024May 21, 2024 | globenewswire.comPurple Biotech Reports First Quarter 2024 Financial ResultsApril 25, 2024 | globenewswire.comPurple Biotech's Randomized Phase 2 CM24 Pancreatic Cancer Study Selected as Late-Breaking Abstract Poster Presentation at ASCO 2024 Annual MeetingApril 17, 2024 | investing.comPurple Biotech Ltd (PPBT)March 28, 2024 | finance.yahoo.comPurple Biotech to Present New Data On its Oncology Drug NT219 at AACR 2024March 14, 2024 | finanznachrichten.dePurple Biotech Ltd.: Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologyMarch 14, 2024 | globenewswire.comPurple Biotech Reports Preclinical Proof of Concept for its Tribody Platform TechnologySee More Headlines Receive PPBT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Purple Biotech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/21/2024Today7/26/2024Next Earnings (Estimated)8/27/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:PPBT CUSIPN/A CIK1614744 Webwww.kitovpharma.com Phone(723) 933-3121Fax972-153-39333121Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$10.00 High Stock Price Target$10.00 Low Stock Price Target$10.00 Potential Upside/Downside+2,400.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.81) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-19,880,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-62.26% Return on Assets-51.53% Debt Debt-to-Equity RatioN/A Current Ratio1.34 Quick Ratio1.34 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.36 per share Price / Book0.29Miscellaneous Outstanding Shares25,238,000Free Float24,486,000Market Cap$10.09 million OptionableOptionable Beta1.03 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Gil Efron CPA (Age 58)M.A., Chief Executive Officer Comp: $455.44kDr. Michael Schickler Ph.D. (Age 66)Head of Clinical & Regulatory Affairs Comp: $264.98kMr. Lior Fhima CPA (Age 47)M.B.A., Chief Financial Officer Mr. Ido Morpurgo B.Sc. (Age 52)L.L.M., Vice President of Operations Key CompetitorsImmuneeringNASDAQ:IMRXLipocineNASDAQ:LPCNAkari TherapeuticsNASDAQ:AKTXEquilliumNASDAQ:EQDaré BioscienceNASDAQ:DAREView All Competitors PPBT Stock Analysis - Frequently Asked Questions How have PPBT shares performed this year? Purple Biotech's stock was trading at $0.78 at the start of the year. Since then, PPBT stock has decreased by 48.7% and is now trading at $0.3999. View the best growth stocks for 2024 here. How were Purple Biotech's earnings last quarter? Purple Biotech Ltd (NASDAQ:PPBT) posted its earnings results on Tuesday, May, 21st. The company reported ($0.16) earnings per share for the quarter, missing analysts' consensus estimates of ($0.15) by $0.01. How do I buy shares of Purple Biotech? Shares of PPBT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:PPBT) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredAlex's "Next Magnificent Seven" StocksToday Alex Green is releasing his new breakdown of AI's "Next Magnificent Seven." So please make some time ...The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Purple Biotech Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Purple Biotech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.